Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Uterine Cervical Neoplasms 1 Ovarian Neoplasms 1 Oncology Patients Receiving Chemotherapy 1 Neoplasms 1 Lung Neoplasms 1 Hypersensitivity 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Breast Neoplasms 1

Interventions

Gemcitabine 109 Paclitaxel 92 Carboplatin 79 pembrolizumab 75 Bevacizumab 75 Surveys and Questionnaires 70 Docetaxel 69 Cisplatin 67 Nivolumab 48 Exercise 48 Capecitabine 48 Cyclophosphamide 47 Sorafenib 43 Fluorouracil 43 Irinotecan 42 Pemetrexed 37 Albumin-Bound Paclitaxel 35 Radiotherapy 34 Dexamethasone 34 Blood Specimen Collection 34 Oxaliplatin 31 Leucovorin 31 Erlotinib Hydrochloride 31 trametinib 30 130-nm albumin-bound paclitaxel 29 Cetuximab 28 Therapeutics 26 Ipilimumab 26 Standard of Care 25 Methods 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Neoplasms × Cetirizine × Clear all

NCT06039137 2024-09-25

H1-Switch

Erasmus Medical Center

Hypersensitivity, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡